Treosulfan as salvage-therapy in metastatic breast cancer – a case report

Introduction: While treatment of metastatic breast cancer (MBC) experienced significant improvement in the past decades by introduction of highly effective drugs as taxanes and anthracyclines, survival remains relatively poor with a 5-year survival rate of 21%. Nonetheless, in some patients long-term survival can be achieved by sequential endocrine and chemotherapy treatment. During long-term treatment resistance and toxicity occur, narrowing treatment choices with every subsequent line of therapy, until no further suitable and approved therapies remain. Treosulfan is an alkylating agent approved for treatment o…